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Abstract 
Background: Recent rodent and human studies provide evidence in support of the fact that CD157, well known 
as bone marrow stromal cell antigen‑1 (BST‑1) and a risk factor in Parkinson’s disease, also meaningfully acts in the 
brain as a neuroregulator and affects social behaviors. It has been shown that social behaviors are impaired in CD157 
knockout mice without severe motor dysfunction and that CD157/BST1 gene single nucleotide polymorphisms are 
associated with autism spectrum disorder in humans. However, it is still necessary to determine how this molecule 
contributes to the brain’s physiological and pathophysiological functions.
Methods: To gain fresh insights about the relationship between the presence of CD157 in the brain and its enzy‑
matic activity, and aberrant social behavior, CD157 knockout mice of various ages were tested.
Results: CD157 immunoreactivity colocalized with nestin‑positive cells and elements in the ventricular zones in E17 
embryos. Brain CD157 mRNA levels were high in neonates but low in adults. Weak but distinct immunoreactivity was 
detected in several areas in the adult brain, including the amygdala. CD157 has little or no base exchange activity, 
but some ADP‑ribosyl cyclase activity, indicating that CD157 formed cyclic ADP‑ribose but much less nicotinic acid 
adenine dinucleotide phosphate, with both mobilizing Ca2+ from intracellular Ca2+ pools. Social avoidance in CD157 
knockout mice was rescued by a single intraperitoneal injection of oxytocin.
Conclusions: CD157 may play a role in the embryonic and adult nervous systems. The functional features of CD157 
can be explained in part through the production of cyclic ADP‑ribose rather than nicotinic acid adenine dinucleotide 
phosphate. Further experiments are required to elucidate how the embryonic expression of CD157 in neural stem 
cells contributes to behaviors in adults or to psychiatric symptoms.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Accumulating evidence suggests that immune-related 
molecules tend to be involved in neuronal development 
and maintenance, and a number of molecules have 
been reported to possess neuronal functions, such 
as complement C4 [1], C1q [2], schnurri-2 [3], and 
CD38 [4]. CD38, originally identified as playing a 
role in hematopoietic cells and leukocytes and in the 
pathogenesis of leukemia and HIV infection [5–8], 
has a critical role in oxytocin (OT) secretion in the 
hypothalamus and in the regulation of social memory and 
social interactions [4, 9, 10]. The mechanism underlying 
the regulation of OT release from oxytocinergic neurons 
involves increases in intracellular Ca2+ concentrations 
by mobilization of Ca2+ from ryanodine receptors [11–
13] to intracellular Ca2+ pools by cyclic ADP-ribose 
(cADPR). CD38, together with CD157, is a member 
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of the ADP-ribosyl cyclase family, which catalyzes the 
formation of cADPR from β-NAD+ [14, 15].
CD157, discovered as bone marrow stromal cell 
antigen-1 (BST-1) by Hirano and colleagues [14–16], is 
a cell-surface molecule that supports pre-B cell growth 
with enhanced expression on bone marrow stromal cell 
lines derived from rheumatoid arthritis patients [17]. 
BST-1, expressed by myeloid cells as a molecule capable 
of signal transduction, was clustered as CD157 after 
gene cloning [14, 17]. CD157 is expressed abundantly 
in the immune tissues of adult mice, e.g., in the spleen 
[5, 7, 13]; therefore, CD157 can be classified as an 
immune molecule. Under inflammatory conditions, the 
homophilic binding of CD157 between the blood vessel 
endothelial cells and lymphocytes promotes lymphocyte 
migration [5, 13]. CD157 is considered to play a role in 
the progression of chronic leukocytic leukemia [7]. In 
addition, CD157 is involved in the pathophysiology of 
various diseases [7, 12]. Its involvement in rheumatoid 
arthritis was implicated in the study that reported its 
discovery [17]. CD157 has been shown to support B 
lymphocyte survival in rheumatoid arthritis, although 
the mechanistic basis of this observation is not yet 
clear. CD157 stimulates neutrophil migration to sites 
of inflammation [5, 13, 15]. The expression of CD157 in 
ovarian carcinoma cells is an indicator of malignancy and 
a higher rate of metastasis [18].
While investigations have intensively focused 
on inflammation and the immune system, little 
information regarding the other functions of CD157 
has been reported. In 2009, however, genome-wide 
association studies (GWASs) identified single nucleotide 
polymorphisms (SNPs) in the CD157/BST1 gene on 
human chromosome 4p15 as new risk factors for 
Parkinson’s disease (PD) in the Japanese population 
[19]. Fifteen subsequent reports confirmed the above 
findings in different populations, including subjects 
of European descent from France, Australia, the UK, 
and the Netherlands, and in Ashkenazi Jews and Asian 
populations, such as the Chinese and Korean populations 
[20–35]. Although six reports yielded contradictory 
findings [36–41], all other GWASs identified intronic 
SNPs in the CD157/BST1 gene that predispose carriers 
to PD. These GWASs indicated that CD157 SNPs 
confer a small (usually 1.1–1.3-fold increase) risk for 
PD. Thus, as suggested by a previous study in Taiwan 
[40], additional genetic and environmental factors may 
be needed to determine the pathogenic role of CD157. 
Nonetheless, it is worth considering how CD157 
contributes to the occurrence of PD or to at least one or 
a variety of PD symptoms. Previously, we examined the 
neuronal function of CD157 by analyzing the phenotypes 
of CD157 deletion mice that would presumably provide 
insights into the neuronal functions of CD157 [42]. 
Interestingly, the results obtained indicated no motor 
dysfunction but social behavioral impairments in CD157 
knockout (KO, CD157−/−) mice such as apathy-, anxiety-, 
and depression-like behaviors [42], which are slightly 
different from the expected phenotypes involving motor 
dysfunction that are commonly observed in PD.
Recently, Wu et  al. reported that nanodiamond 
particles can be transferred into transplanted 
CD45−CD54+CD157+ lung stem/progenitor cells [43]. 
Yilmaz et al. reported that fasting results in the activation 
of the mTORC1 pathway and induction of CD157 in 
Paneth cells in the adult mouse intestine [44, 45]. The 
product of the CD157 catalyzed reaction, cADPR, 
inhibits differentiation of intestinal stem cells to acinar 
cells, and thus facilitates proliferation of intestinal stem 
cells. These results suggest that CD157 is an enteric 
protein and that CD157 plays a role in the stem cells of 
two organs. However, the question about the presence of 
CD157 in neuronal stem cells remains unanswered.
Here, we present new data to evaluate our previous 
findings regarding the functional roles of CD157 in the 
nervous system. We also present results with CD38 for 
comparison. Finally, we discuss the limitations of our 
results and possibilities about the role of CD157 in the 
progression of PD in relation to psychiatric symptoms as 
well as other psychological disorders.
Results
We used polyclonal antiserum raised in rabbits against 
a chimeric fusion protein of murine CD157 that had 
been preabsorbed with CD38, to examine its specific-
ity for CD157. In C57BL/6N wild-type adult mice, CD157 
immunoreactivity was shown in the white pulp region 
of the spleen, where CD157 was enriched (CD157+/+, 
Fig.  1), while no staining was observed in CD157 knock-
out (CD157−/−) mice. These immunofluorescence results 
clearly indicate that our antibody is specific to mouse 
CD157. On the basis of this specificity, we decided to assess 
CD157 immunoreactivities in the brains of embryos.
Presence of CD157 in brain stem cells
Strong staining for CD157 in immunofluorescence 
images obtained using a confocal microscope was seen 
in the hypothalamus of E17 embryos (Fig.  2). CD157 
immunoreactivity was detected in the cytoplasm or at 
the cell surface of many but not all nestin-positive cells 
in the ventricular and subventricular zones beside the 
third ventricle (Fig.  2a). This colocalization was exam-
ined further by quantitative colocalization analysis (46). 
As shown in Fig. 2b, three representative cells show that 
the degree of overlap of the fluorescence signals is greater 
than 50%. We estimate that this colocalization is limited 
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to the embryonic stem cells. However, we did not exam-
ine the presence of CD157 in adult mouse brain stem 
cells, although this is an interesting topic and should be 
examined further.
mRNA expression in neonates and adult male mice
In support of the above observation and as reported pre-
viously [42], the brain CD157 mRNA levels decreased 
markedly 7–14  days postnatally from the relatively high 
levels in the embryonic period (shown in Fig.  3a (n =  5 
mice)). This time course is the opposite of that of CD38, 
whose mRNA levels on postnatal day 14 represent a >25-
fold increase from that on postnatal day 1 (n =  4 mice) 
[45].
The levels of CD157 mRNA expression in different 
brain regions (cerebrum, cerebellum, hypothalamus, and 
striatum) in adult male C57BL/6 mice were extremely 
low compared to that in the spleen (P  <  0.001, n  =   5) 
(One-way ANOVA, F2,40  =  195.94, P  <  0.0001; Fig. 3b; 
Additional File 1). In marked contrast, CD38 mRNA was 
expressed abundantly in the four brain regions exam-
ined, with no significant difference in density among 
regions, although these densities were significantly lower 
than that in the spleen (P  <  0.05 for the hypothalamus; 
P  <   0.001 for the cerebellum and striatum; P  <   0.0001 
for the cerebrum: One-way ANOVA, P   <   0.0001, 
F4,20  =   9.78, n =  4). Taken together, these mRNA and 
protein expression studies show the quite distinct expres-
sion profiles of CD38 and CD157. However, for a more 
quantitative comparison, it is necessary to analyze brain 
samples by using the SYBR–Green I-based reverse tran-
scription-quantitative polymerase chain reaction assay.
Immunohistochemistry in the adult brain
The expression of CD157/BST-1 protein in the brains 
of adult male mice was examined using our polyclonal 
antiserum [42]. Weak but distinct immunoreactivity 
was detected in the amygdala (basolateral amygdaloid 
nucleus, anterior part (BLA; Fig.  4a, b)) of CD157+/+ 
mouse, but identical immunoreactivities were not found 
in CD157−/− mice (Fig.  4c, d). CD157 immunoreactiv-
ity was detected in the central amygdaloid nucleus (CeL; 
Fig. 4e), medial amygdaloid nucleus, posteroventral part 
(MePV, Fig.  4h), somatosensory cortex (primary soma-
tosensory cortex, barrel field (S1BF; Fig.  4f )), medial 
preoptic area (MPOA; Fig. 4i), secondary somatosensory 
cortex (S2; Fig.  4g), and arcuate hypothalamic nucleus 
(Arc; Fig. 4j) of the CD157+/+ mouse brain. Little or no 
immunoreactivity was detected in the other brain regions 
examined: the hippocampus, piriform cortex, perirhi-
nal cortex, retrosplenial granular cortex c region or the 
nucleus accumbens. This expression pattern of CD157 
corresponded well with our previous findings [42], 
although further examinations may be necessary because 
the volume of the amygdala was smaller in KO mice than 
in control mice [42].
Enzymatic activity of CD157
An additional issue to be resolved is whether the func-
tions of CD157 in neural stem cells as well as brain cells 
Fig. 1 Specificity of rabbit antiserum for murine CD157. Representative images of CD157 immunoreactivity (green) in the spleens of wild‑type 
(CD157+/+; a) and CD157 KO (CD157−/−; b) adult male mice. The tissues were incubated with the rabbit antiserum against murine CD157. After 
washing, the sections were treated with Alexa Fluor 488
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Fig. 2 Immunohistochemical analysis of CD157 expression in the embryonic brain. a Representative images from the E17 embryonic hypothala‑
mus: CD157 stained in green, nestin in red, and the nucleus in blue. b An enlarged image indicated in (a) (a square enclosed by a dotted line) shows 
the colocalization patterns of CD157 (green) and nestin (red) in individual cells. Colocalization diagrams of green (CD157) and red (nestin) channels 
in three cells indicated in the image illustrate overlap in the individual cells. The X‑ and Y‑axes indicate cell size in µm; the Z‑axis‑fluorescence signal 
intensity. Colocalization is estimated by calculating Pearson’s correlation coefficient (PCC) and overlap coefficient (OC). Intermediate zone (IZ), 
subventricular zone (SVZ), ventricular zone (VZ), and third ventricle (3V)
Fig. 3 CD157 and CD38 mRNA expression in the brain. a Schematic drawing of the time course of mRNA expression in the whole brains of pups 
on postnatal days 1, 7, and 14. One hundred percent refers to values on postnatal days 1 or 14 for CD157 and CD38, respectively. Data for CD157 
and CD38 were obtained from previous reports by Lopatina et al. [42] and Higashida et al. [45], respectively (n = 5 mice for CD157 and n = 4 mice 
for CD38). b Quantitative data obtained by RT‑PCR analysis of CD157 and CD38 mRNA expression in four brain regions of adult male mice using 
β‑actin mRNA as an internal control. Values show percentages of means  ±  S.E.M. (n  =  5 independent experiments) of CD157/actin with values in 
the spleen set to 100. One‑way ANOVA reveals F2,40 = 195.94, P < 0.0001 for CD157 and P < 0.0001, F4,20 = 9.78 for CD38. Significant from density of 
spleen at *P < 0.0001, ##P < 0.001, #P < 0.05, respectively. Cbr cerebrum, Cbl cerebellum, Hyp hypothalamus, Str striatum
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are mediated by the enzymatic products of CD157, 
cADPR and nicotinic acid adenine dinucleotide phos-
phate (NAADP), which mediate Ca2+ mobilization from 
Ca2+ pools [12, 46]. This was originally reported in bone 
marrow mesenchymal stem cells by Tao et al. [47], who 
showed that cADPR is a novel regulator of Ca2+ oscilla-
tions in human mesenchymal stem cells. They reported 
that cADPR permeates the cell membrane through nucle-
oside transporters and increases Ca2+ oscillations by the 
activation of another molecule, the TRPM2 cation chan-
nel, resulting in enhanced phosphorylation of ERK1/2, 
and thereby stimulating human mesenchymal stem cell 
proliferation.
CD157 and CD38 belong to a family with ADP-ribo-
syl cyclase activity. The ADP-ribosyl cyclase activity of 
CD157 is weaker than that of CD38 [6]. However, it is not 
clear whether CD157 has other enzyme activities, such 
as NAD glycohydrolase or NAD base exchange activities. 
The product of base exchange is NAADP [6, 12]. NAADP 
also has Ca2+ mobilization activity from different Ca2+ 
pools [12, 48].
We examined whether CD157 has two enzyme activities, 
and especially its base exchange activity, by independently 
transfecting HEK cells with mouse CD157 or CD38 genes. 
The representative western blot analysis shows protein 
bands of expressed CD157 and CD38 (Fig.  5a). First, the 
ADP-ribosyl cyclase activity of CD157-transfected cells 
was higher than that of vector-transfected control cells 
(P  <  0.001) and lower than that of CD38-transfected cells 
(P  <  0.0001; F8,34 = 9.01, n = 3, one-way ANOVA; Fig. 5b; 
Additional File 2). Figure  5c shows that CD157 has little 
or no base exchange activity (F2,7   =   36.26, P   <   0.0001, 
n = 3): CD157-transfected cells showed no or little NAADP 
synthetic activity, with no discernable differences from 
vector-transfected control cells. In sharp contrast, CD38-
transfected cells possessed significantly higher NAADP 
synthetic activity (P   <   0.0001) compared to control cells 
(F2,7  =  36.26, n = 3; Fig. 5c; Additional File 2). These results 
suggested that the functional role of CD157 likely stems 
from the production of cADPR rather than NAADP. It was 
also confirmed that cADPR production by CD157 is not 
high, unlike CD38.
Social behavior in CD157 or CD38 KO mice
Severe anxiety-like and depression-related behaviors 
were observed previously in CD157 KO male mice in 
the light–dark transition test, a standard anxiety-related 
behavioral test [42]. The transition from a light to a dark 
arena was significantly shorter in the CD157 KO mice 
compared with the controls (two-tailed Student’s t test, 
Fig. 4 Immunohistochemical analysis of CD157 expression in the brains of adult male mice. Frozen sections of wild‑type (CD157+/+) and knockout 
(CD157−/−) mice were incubated with rabbit antiserum against murine CD157. After washing, the sections were treated with Alexa Fluor 488. 
Representative photographs show CD157 (green) and Hoechst‑stained nuclei (DAPI, blur) immunoreactivity in CD157+/+ a,b, e–j and CD157−/− c, d 
mouse brains. The insets are enlarged areas indicated in the lower magnification photographs. Brain areas examined are: a–d basolateral amygda‑
loid nucleus, anterior part (BLA); e central amygdaloid nucleus (CeL); f primary somatosensory cortex (S1BF); g secondary somatosensory cortex 
(S2); h medial amygdaloid nucleus, posteroventral part (MePV); i medial preoptic area (MPOA); j arcuate hypothalamic nucleus (Arc). The scale bar 
represents 100 μm
Page 6 of 12Higashida et al. BMC Neurosci  (2017) 18:35 
P   <   0.05; Fig.  6; Additional File 3), suggesting anxiety 
related to a novel environment. For comparison, we also 
performed the test in CD38 KO mice. While the entry 
frequency was markedly different, probably because of 
the different backgrounds of the two strains, we found 
no behavioral differences between CD38 KO and wild-
type ICR mice (Fig. 6 left panel; Additional File 3). These 
observations suggested that anxiety related to a novel 
environment is a characteristic of CD157 KO mice, but 
not CD38 KO mice.
Finally, the phenotype in the open field was examined 
in wild-type and CD157−/− mice. The time spent in the 
inside zone in an open field test was significantly shorter 
for CD157 KO mice than wild-type controls (Fig. 7a). The 
interaction time with a social target mouse in the central 
arena was markedly shorter in CD157 KO mice than in 
wild-type controls (Fig. 7b), as judged from the duration of 
immobility. The immobility time was approximately half of 
the total time spent in the inside zone in both the KO and 
wild-type mice. Interestingly, this was rescued by a sin-
gle intraperitoneal injection of OT with both time in the 
inside zone and immobility time increasing significantly 
(Fig.  7a, b; Additional File 4). The analysis of the results 
by two-way ANOVA revealed significant treatment (PBS 
vs. OT) x genotype (wild-type vs. KO) interaction effects 
(F2,42 = 6.041, P = 0.0005; Fig. 7a). Tukey’s multiple com-
parison tests detected significant differences in genotype 
(F1,42 =  23.08, P =  0.0001) and treatment (F2,42 =  11.06, 
P  =  0.0001) effects. Two-way ANOVA detected signifi-
cant treatment (PBS vs. OT) × genotype (wild-type vs. 
KO) interaction effects (F2.42 = 5.674, P = 0.0066; Fig. 7b). 
Tukey’s post hoc tests demonstrated significant differ-
ences in genotype (F1,42 = 17.49, P = 0.001) and treatment 
(F2,42 = 11.42, P = 0.0001) effects.
Discussion
The most important result of the present study was the 
finding that the function of CD157 is mediated solely by 
the second messenger cADPR and not NAADP. This was 
Fig. 5 Enzymatic synthesis of cADPR and NAADP by FLAG‑fusion proteins (mBST‑1 and mCD38). a Western blot analysis of FLAG‑fusion proteins 
from cell lysates of vector (50 µg), mouse BST‑1 (mBST‑1, 50 µg), and mouse CD38 (mCD38, 10 µg) using anti‑FLAG antibody. b, c Enzyme activities for 
cADPR and NAADP synthesis were measured by incubation of purified FLAG‑fusion proteins (vector, mBST‑1 or mCD38) with appropriate substrates 
as described in the “Methods” section. *P < 0.001, **P < 0.0005, ***P < 0.0001. The mean ± S.E.M. of three independent experiments is shown
Fig. 6 Behaviors of wild‑type (C57BL/6 N for CD157 and ICR for 
CD38) or CD157 and CD38 knockout mice in the light–dark transition 
test. Values are transition numbers between the two compartments 
(light to dark zones). The results are expressed as the mean ± S.E.M., 
n = 5–10, *P < 0.05 compared with wild‑type controls (two‑tailed 
Student’s t test)
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the first clear demonstration of the differential action of 
CD157 in generating the Ca2+-related second messengers. 
CD38 is known to have a robust ability to catalyze cADPR 
as well as NAADP formation in several tissues, including 
the islets of Langerhans [4, 6, 8, 9, 12, 49]. NAADP, as a 
Ca2+ signaling messenger, plays an important role in 
insulin secretion [12]. However, this raises a critical 
question about CD157 mediating its functions in the 
nervous system and stem cells through cADPR but not 
NAADP formation. A good example is the crucial role of 
both cADPR and CD157 in intestinal Paneth cells [44, 45].
The second important finding was that CD157 immu-
noreactivity colocalized with nestin-positive cells and ele-
ments, probably neuroprogenitor or neurolineage cells, in 
the subventricular zone of embryos. Our results indicated 
that CD157 is a functional molecule, or at least is present 
in stem cells, as shown in the Paneth cells in the digestive 
tract [44, 45], lung [43], and mesenchymal cells [47]. The 
functional roles in these stem cells may be due to cADPR, 
as shown in Paneth cells. However, in the nervous system, 
CD157 may play a role in neuronal migration during neural 
stem cell proliferation and neurogenesis. It has been shown 
that CD157 binds with members of the integrin family [50]. 
Furthermore, integrin β3 and the serotonin transporter 
interact to modulate serotonin uptake in the mouse brain 
[51]. Therefore, it would be interesting to examine whether 
cADPR facilitates the self-renewal of neural stem cells and 
whether a tertiary complex of CD157, integrin, and the ser-
otonin transporter is formed in the mouse brain.
CD157 is a sister molecule of the CD38 cell-surface 
antigen with ADP-ribosyl cyclase activity [5, 6, 12], but the 
phenotypes of CD157 KO and CD38 KO mice are quite 
different [4, 9–11, 46]. The role of CD38 in OT secre-
tion into the brain has been established [4, 9–11]; CD38 
mediates cADPR production, TRMP2 and ERK1/2 acti-
vation, Ca2+-mobilization, and OT release [47] (Fig.  8). 
Additionally, CD38 is involved in OT release by activat-
ing molecular cascades of OT autoregulation [4, 10]. In 
contrast, CD157 binds with the serotonin transporter and 
integrin β and invokes multiple circuits to control anxi-
ety- and depression-like behaviors [13, 18, 42, 49]. CD157 
plays a role in cADPR-induced OT release, which may not 
be identical to that of CD38. (Figure  8). The deficiency 
of CD157 leads to aberrant behaviors, such as increased 
anxiety. A decrease in volume of the amygdala, an impor-
tant constituent of the “social brain,” might be caused by 
a loss of this molecule in the neural stem cells during the 
developmental stages [42].
The behavioral impairments in CD157 KO mice were 
rescued by OT, probably because OT directly targets 
the intracellular signaling networks in the social brain 
downstream of CD157, which might be independent of 
CD38 and its downstream signaling networks (Fig.  8). 
This observation suggests that OT can be used for the 
treatment of social avoidance in psychological disorders. 
Furthermore, whether we can extend the results obtained 
in the mouse to human behavioral recovery is of inter-
est, especially since there have been reports regarding 
the effectiveness of OT for impaired social interaction in 
cases of autism spectrum disorder (ASD) [53–55].
It has been shown that SNPs of CD38 are associated with 
ASD [57–62]. As CD157 is abundant in the embryonic 
Fig. 7 Social avoidance of adult male mice in the open field test. The test mouse was exposed to the open field for 20 min. A social (male mouse) 
target was present at the center of the inside arena. Time in the inside zone (a) and time spent immobile in the inside zone (b) were observed 
in wild‑type (blue), CD157 KO mice (gray), and CD157 KO mice given an intraperitoneal injection of 100 ng/ml × 0.3 ml of OT (orange) are shown. 
Data are means  ±  S.D., n  =  8. Two‑way ANOVA revealed significant treatment (PBS vs. OT) x genotype (wild‑type vs. KO) interaction effects in a 
(F2,42 = 6.041, P = 0.0005) and b (F2.42 = 5.674, P = 0.0066). Values in CD157−/− mice treated with OT are significantly higher than those in CD157−/− 
mice with no treatment or those treated with PBS at P  <  0.001 in (a) and (b). *P < 0.001 compared OT treatment with no treatment or treated with 
PBS in CD157−/− mice (Tukey’s post hoc test)
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stages, speculation regarding an association between the 
SNPs of CD157 and ASD is understandable. Recently, 
we found associations between ASD and three SNPs of 
CD157 (rs4301112, rs28532698, and rs10001565). These 
SNPs have chromosomal locations (from chr4:15717226 
to chr14:15722573) distinct from those associated with PD 
(chr14:15725766 to chr4:15737937) [63].
Conclusions
The results of the present study indicate a novel neuronal 
role for CD157 in addition to its known functions in the 
digestive and immune systems. Therefore, CD157 can be 
referred to as a neuro-entero-immunological regulator 
[14]. The less abundant expression of CD157 in the 
adult brain raises questions about the common features 
associated with the late onset of PD. Because CD157 is 
expressed abundantly in the embryonic brain, it may 
be involved in the processes of neuronal development 




CD157/BST1 KO and CD38 KO mice were cre-
ated as described previously [4, 15, 64]. Frozen 
CD157+/− fertilized oocytes were routinely inoculated 
into pseudopregnant foster mothers. Offspring were gen-
otyped as described previously [15]. CD157 and CD38 
KO mice were maintained by crossbreeding homozygous 
mutant mice. Slc:ICR (CD-10) outbred male mice (10–
12 weeks old, 30–35 g body weight) were obtained from 
Japan SLC Inc. (Hamamatsu, Japan) via a local distributor 
(Sankyo Laboratory Service Corporation, Toyama, Japan). 
In over half of the experiments, the offspring of wild-
type mice were bred in our laboratory colony, weaned 
at 25–30 days of age, and housed in same-sex groups of 
3–5 animals. In general, 4–5 males were kept in one cage 
in the animal center under standard conditions (24  °C; 
12/12-h light/dark cycle, with lights on at 8:45 a.m.) with 
food and water ad libitum. The breeding pairs were main-
tained separately (1 pair per cage). After parturition, the 
body weight of both male and female pups was measured 
daily in 10 pairs consisting of approximately 40 pups. At 
21 days old, the offspring were removed for weaning and 
housed in same-sex sibling pairs. Subsequently, viability 
was assessed. All animal experiments were carried out in 
accordance with the Fundamental Guidelines for Proper 
Conduct of Animal Experiment and Related Activities in 
Academic Research Institutions under the jurisdiction of 
the Ministry of Education, Culture, Sports, Science and 
Fig. 8 The scheme of CD38‑ and CD157‑mediated molecular pathways in relation to social behavior. The scheme shows the possible molecular 
pathways of cADPR formation, OT release, and behavioral effects related to CD38 and CD157 in OT neurons in the social brain
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Technology of Japan and were approved by the Commit-
tee on Animal Experimentation of Kanazawa University.
CD157 immunostaining
Embryos were removed from anesthetized dams. Adult 
male mice were anesthetized and perfused intracardially 
with cold phosphate-buffered saline (PBS) followed by 
cold 4% paraformaldehyde (PFA) in PBS. Their brains 
were removed and fixed in 4% PFA solution overnight at 
4 °C. Sections were preincubated in blocking solution (3% 
bovine serum albumin and 0.3% Triton X-100 in PBS) for 
1 h and then incubated overnight with an antibody against 
CD157. Anti-murine CD157 (BST-1) antiserum was 
prepared by immunizing rabbits with a chimeric fusion 
protein of murine CD157 and the Fc portion of human 
IgG1 (mBST-1Fc), and the reactivities to human IgG and 
murine CD38 were absorbed by human IgG Sepharose 
6 and the transfectant, BAFmCD38, respectively, as 
described [42]. Goat anti-nestin antibody (sc-20978, 
1:1000; Santa Cruz Biotechnology Inc., USA) was added 
to blocking solution. After three washes with washing 
buffer, the sections were incubated with goat anti-rabbit 
and donkey anti-goat IgG antibodies coupled to Alexa 
Fluor 488 and 594 (Invitrogen, Carlsbad, CA), respectively, 
and DAPI (Wako, Osaka, Japan) in blocking solution 
for 1  h at room temperature. Imaging was performed 
with an Olympus IX71 fluorescence microscope (Tokyo, 
Japan). We identified CD157-positive cells within a 
specific size range and above a constant threshold level 
of staining as follows: fluorescence diameter   <   15  μm 
and intensity  >   50 (arbitrary units, a.u.) [65, 66]. The 
colocalization of CD157 and nestin immunoreactivities 
was estimated using Pearson’s correlation coefficient 
(PCC) and overlap coefficient (OC) with Olympus 
FluoView software (Ver.4.0a) [67].
RT‑PCR
Total RNA was isolated from mouse brain subregions 
using TRIzol Reagent (Invitrogen). cDNA was synthesized 
from 0.5 μg of total RNA using ReverTra Ace-α (Toyobo, 
Osaka, Japan) according to the manufacturer’s protocol. 
PCR was performed on a Mastercycler ep gradient S 
(Eppendorf, Hamburg, Germany) under the following 
conditions: 1 cycle at 94 °C for 30 s, followed by 25 or 30 
cycles at 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 40 s, 
with a final extension step at 72 °C for 1 min. The primer 
sequences used have been reported previously [15, 42]. 
RT-PCR products were separated electrophoretically 
on 1.2% gels and stained with ethidium bromide. Band 
intensity was measured from photographs using ImageJ. 
The data presented shows the ratio of CD157 intensity to 
the intensity of β-actin in the same sample.
Plasmids and transfection
Flag-mBST-1 and Flag-mCD38 cDNA were cloned 
from mouse spleen cDNA. mBST-1 and mCD38 
were amplified by PCR using mBST-1-EcoR I forward 
(5′-CGGAATTCAATGGCTGTCCAGGGAGGCCT-3′), 
mBST-1-Xba I reverse (5′-GCTCTAGACGCCTGA-
GAACTTGAAGCCAAAG-3′), mCD38-EcoR I forward 
(5′-GGAATTCCATGGCTAACTATGAATTTAGCC-3′) 
and mCD38-Sal I reverse (5′-ACGCGTCGACGCGTAT-
TAAGTCTACACGATGGG-3′) primers. The PCR prod-
ucts were ligated into a pFLAG-CMV2 expression vector. 
HEK293 cells were transfected with the plasmids using 
Lipofectamine 2000 transfection reagent (Invitrogen) 
according to the manufacturer’s instructions. Cells were 
used 24 h post-transfection.
Measurement of ADP‑ribosyl cyclase activity
Purified proteins (mBST-1, mCD38) were incubated 
with 0.5 mM β-NAD at 37  °C for 1 h in 20 mM Tris–
HCl buffer (pH 7.2) with 0.1% Triton-X 100. Samples 
were treated with 0.6  M perchloric acid (PCA), and 
precipitates were removed by centrifugation. PCA 
was removed by mixing the aqueous sample with 3 
parts 2  M KHCO3. After centrifugation at 15,000×g 
for 10  min, the aqueous layer was collected and neu-
tralized with 20  mM sodium phosphate (pH 8.0). The 
enzyme product, cADPR, was measured by modifica-
tion of the cycling method described previously [68]. 
To remove all contaminating nucleotides, the samples 
were incubated overnight with the following hydrolytic 
enzymes at 37  °C: 0.44 units/ml nucleotide pyrophos-
phatase, 12.5 units/ml alkaline phosphatase, 0.0625 
units/ml NAD glycohydrolase, and 2.5  mM MgCl2 in 
20  mM sodium phosphate buffer (pH 8.0). Enzymes 
were removed by filtration using Centricon 3 filters. To 
convert cADPR to β-NAD+, the samples (0.1 ml/tube) 
were incubated with 50 μl of a cycling reagent contain-
ing 0.3  μg/ml Aplysia ARC, 30  mM nicotinamide, and 
100  mM sodium phosphate (pH 8.0) at room temper-
ature for 30  min. The samples were further incubated 
with the cycling reagent (0.1 ml) containing 2% ethanol, 
100  μg/ml alcohol dehydrogenase, 20  μM resazurin, 
10  μg/ml diaphorase, 10  μM riboflavin 5′-phosphate, 
10  mM nicotinamide, 0.1  mg/ml bovine serum albu-
min (BSA), and 100  mM sodium phosphate (pH 8.0) 
at room temperature for 2  h. An increase in resorufin 
fluorescence was measured at 544  nm excitation and 
590  nm emission wavelengths using a fluorescence 
plate reader (Molecular Devices Corp., Spectra-Max 
GEMINI). Various known concentrations of cADPR 
were also included in the cycling reaction to generate a 
standard curve.
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Measurement of NAADP synthesis activity
NAADP synthesizing activity of the purified proteins 
(mBST-1, mCD38) was measured using a combination 
of the base-exchange reaction and the cycling method 
as described previously with modifications [69, 70]. 
The enzyme product, NAADP, was measured following 
incubation of the proteins with 0.5  mM NADP and 
10 mM nicotinic acid at 37  °C for 1 h in 50 mM sodium 
acetate-acetic acid buffer (pH 4.5). Samples were treated 
with 0.6  M PCA, and precipitates were removed by 
centrifugation. PCA was removed by mixing the aqueous 
sample with 3 parts 2  M KHCO3. After centrifugation 
at 15,000×g for 10  min, the aqueous layer was collected 
and neutralized with 20 mM sodium phosphate (pH 8.0). 
To remove all contaminating nucleotides, the samples 
were incubated overnight with the following hydrolytic 
enzymes at 37  °C: 2.5 units/ml apyrase, 0.125 units/ml 
NAD glycohydrolase, 2  mM MgCl2, 1  mM NaF, 0.1  mM 
PPi, and 0.16 mg/ml NMN-adenylyl transferase in 20 mM 
sodium phosphate buffer (pH 8.0). Enzymes were removed 
by filtration using Centricon 3 filters. After the hydrolytic 
treatment, alkaline phosphate (10 units/ml) was added to 
convert NAADP to NAAD, and the samples incubated 
overnight at 37  °C. The alkaline phosphate was removed 
by filtration using Centricon 3 filters. The samples 
were further incubated with the cycling reagent (30  μl) 
containing 2% ethanol, 100 μg/ml alcohol dehydrogenase, 
20  μM resazurin, 10  μg/ml diaphorase, 10  μM riboflavin 
5′-phosphate, 10 mM nicotinamide, 0.1 mg/ml BSA, and 
100 mM sodium phosphate (pH 8.0) at room temperature 
for 4  h. An increase in the resorufin fluorescence was 
measured at 544  nm excitation and 590  nm emission 
wavelengths using a fluorescence plate reader (Spectra-
Max GEMINI). Various known concentrations of NAADP 
were also included in the cycling reaction to generate a 
standard curve.
Light–dark transition test
The light–dark transition was measured using the light–
dark test chamber [42]. One chamber was brightly 
illuminated (250  lx), whereas the other was dark (2  lx). 
Mice were placed in the light arena and were allowed to 
move freely between the two chambers for 600  s. Each 
male mouse was placed in the center of the light chamber, 
and the mouse was allowed to run freely between the two 
chambers for 10 min. The trial was recorded for 10 min 
using the ANY-maze video system [66]. Latency to enter 
(defined by all four paws entering), time spent, entries, 
and distance traveled in the light chamber were recorded.
Social avoidance test
Social avoidance behavior toward an unfamiliar 
C57BL/6  N mouse was measured in a two-stage social 
interaction test [42]. In the first 10-min test (target 
absent), the experimental mouse was allowed to 
freely explore a square-shaped arena (600  ×  600  mm) 
containing a wire mesh cage (70 × 90 × 70 mm and bars 
spaced 5  mm apart) placed in the center of the arena. 
In the second 20-min test, the experimental mouse was 
reintroduced back into the arena with an unfamiliar 
C57BL/6  N male mouse in a wire mesh cage. Video 
tracking software (ANY-maze) was used to measure 
the amount of time the experimental mouse spent in 
the “interaction zone” (300  ×  300  mm). Behavior was 
measured in mice at 20  min after an intraperitoneal 
injection of 0.3 ml of OT (100 ng/kg body weight) or PBS 
or without any treatment.
Statistical analysis
Data were analyzed using one-way or two-way analysis 
of variance (ANOVA). Post hoc comparisons were 
conducted only when the main effect was statistically 
significant. P-values for multiple comparisons were 
adjusted using Bonferroni’s correction. All analyses were 
conducted using STATA data analysis and statistical 
software (StataCorp LP, College Station, TX, USA).
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